NASDAQ:YMAB Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis $12.53 +0.20 (+1.62%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$12.24▼$12.6750-Day Range$11.27▼$13.0852-Week Range$4.60▼$20.90Volume128,581 shsAverage Volume370,508 shsMarket Capitalization$549.82 millionP/E RatioN/ADividend YieldN/APrice Target$17.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Y-mAbs Therapeutics alerts: Email Address Y-mAbs Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside42.5% Upside$17.86 Price TargetShort InterestBearish11.70% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 4 Articles This WeekInsider TradingSelling Shares$1.20 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.52) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.22 out of 5 starsMedical Sector587th out of 936 stocksPharmaceutical Preparations Industry269th out of 436 stocks 3.2 Analyst's Opinion Consensus RatingY-mAbs Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 5 buy ratings, no hold ratings, and 2 sell ratings.Amount of Analyst CoverageY-mAbs Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Y-mAbs Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.70% of the float of Y-mAbs Therapeutics has been sold short.Short Interest Ratio / Days to CoverY-mAbs Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Y-mAbs Therapeutics has recently increased by 18.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldY-mAbs Therapeutics does not currently pay a dividend.Dividend GrowthY-mAbs Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for YMAB. Previous Next 3.2 News and Social Media Coverage News SentimentY-mAbs Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Y-mAbs Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for YMAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Y-mAbs Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Y-mAbs Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,203,925.00 in company stock.Percentage Held by Insiders21.50% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.85% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Y-mAbs Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.52) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Y-mAbs Therapeutics is -25.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Y-mAbs Therapeutics is -25.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioY-mAbs Therapeutics has a P/B Ratio of 5.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Y-mAbs Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Y-mAbs Therapeutics Stock (NASDAQ:YMAB)Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.Read More YMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart YMAB Stock News HeadlinesJuly 22, 2024 | globenewswire.comPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMABJuly 19, 2024 | americanbankingnews.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Recommendation of "Hold" by BrokeragesJuly 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…July 1, 2024 | globenewswire.comY-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial OfficerJune 7, 2024 | globenewswire.comY-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual MeetingJune 5, 2024 | globenewswire.comY-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development OfficerJune 1, 2024 | globenewswire.comY-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual MeetingJune 1, 2024 | globenewswire.comY-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual MeetingJuly 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…May 9, 2024 | finance.yahoo.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call TranscriptMay 9, 2024 | seekingalpha.comY-mAbs: There's A Ceiling Here SomewhereMay 9, 2024 | finance.yahoo.comY-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 9, 2024 | finance.yahoo.comQ1 2024 Y-mAbs Therapeutics Inc Earnings CallMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Y-Mabs Therapeutics Amid Strong Danyelza Sales and Promising SADA Radiotherapy PlatformMay 7, 2024 | investorplace.comYMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | tmcnet.comY-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsMay 7, 2024 | finance.yahoo.comY-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue EstimatesApril 26, 2024 | globenewswire.comY-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024See More Headlines Receive YMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:YMAB CUSIPN/A CIK1722964 Webwww.ymabs.com Phone(646) 885-8505FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$17.86 High Stock Price Target$26.00 Low Stock Price Target$5.00 Potential Upside/Downside+42.5%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,430,000.00 Net Margins-25.64% Pretax Margin-24.79% Return on Equity-21.40% Return on Assets-16.91% Debt Debt-to-Equity RatioN/A Current Ratio6.15 Quick Ratio5.67 Sales & Book Value Annual Sales$84.82 million Price / Sales6.48 Cash FlowN/A Price / Cash FlowN/A Book Value$2.32 per share Price / Book5.40Miscellaneous Outstanding Shares43,880,000Free Float34,448,000Market Cap$549.82 million OptionableOptionable Beta0.66 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Thomas Gad (Age 53)Founder, Chief Business Officer & Vice Chairman Comp: $1.05MMr. Bo Kruse (Age 51)Executive VP, Secretary, Treasurer & CFO Comp: $685.02kMs. Susan Smith (Age 53)Senior VP & Chief Commercial Officer Comp: $710kMr. Michael Rossi (Age 53)CEO, President & Director Mr. Joris Wiel Jan Wilms (Age 50)Senior VP & COO Dr. Torben Lund-Hansen M.Sc. (Age 73)Ph.D., Senior VP & CTO Dr. Steen Lisby M.D. (Age 60)M.Sc., Senior VP & Chief Scientific Officer Comp: $393.99kMs. Courtney DuganVice President of Investor RelationsDr. Vignesh Rajah M.B.A. (Age 59)MBBS, Senior VP & Chief Medical Officer Comp: $406.27kMore ExecutivesKey CompetitorsHeron TherapeuticsNASDAQ:HRTXAurinia PharmaceuticalsNASDAQ:AUPHAmarinNASDAQ:AMRNMersana TherapeuticsNASDAQ:MRSNGeneration BioNASDAQ:GBIOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 8,974 shares on 7/26/2024Ownership: 0.276%Thomas GadSold 35,000 sharesTotal: $421,050.00 ($12.03/share)Gerard BerSold 722 sharesTotal: $8,664.00 ($12.00/share)Bo KruseSold 31,371 sharesTotal: $378,647.97 ($12.07/share)Boston PartnersBought 34,165 shares on 5/28/2024Ownership: 0.078%View All Insider TransactionsView All Institutional Transactions YMAB Stock Analysis - Frequently Asked Questions How have YMAB shares performed this year? Y-mAbs Therapeutics' stock was trading at $6.82 at the start of the year. Since then, YMAB stock has increased by 83.7% and is now trading at $12.53. View the best growth stocks for 2024 here. How were Y-mAbs Therapeutics' earnings last quarter? Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) released its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.03. The company earned $19.93 million during the quarter, compared to analyst estimates of $22.06 million. Y-mAbs Therapeutics had a negative trailing twelve-month return on equity of 21.40% and a negative net margin of 25.64%. When did Y-mAbs Therapeutics IPO? Y-mAbs Therapeutics (YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager. Who are Y-mAbs Therapeutics' major shareholders? Y-mAbs Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.28%). Insiders that own company stock include Biotech Aps Wg, Johan Wedell-Wedellsborg, Bo Kruse, Thomas Gad and Vignesh Rajah. View institutional ownership trends. How do I buy shares of Y-mAbs Therapeutics? Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Y-mAbs Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV) and Occidental Petroleum (OXY). This page (NASDAQ:YMAB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
